Dr. Harriet Feilotter, PhD, FCCMG

Canadian Cancer Trials Group, Senior Scientist

Dr. Feilotter’s research is focused on the validation and implementation of biomarkers to be used in the screening, diagnosis or treatment of human cancer. Her research includes the study of DNA and RNA-based biomarkers in a variety of cancers, including solid tumours and hematologic neoplasms.  She is focused on understanding and standardizing the evidence base that accompanies successful transition of a biomarker from research to the clinical setting, as well as identifying best practices for clinical laboratory approaches to molecular biomarker assessment.

Through her engagement with OICR, CCO, Ontario Health and others, she is looking to bridge the gap between research and the clinical application of biomarker findings.  As a member of the Indoc Research team she also has a focus on data, including the proper handling and storage of biomarker data, the preprocessing pipelines required to ensure high quality data, and the analytic pipelines needed to deliver and share effective clinical tools.  She brings her expertise in these areas, as well as her connections to provincial and national advisory and oversight bodies to help to align CCTG biomarker-stratified trial approaches with current and emerging best practices.

Areas of expertise: Genomics, genetics, biomarkers, variant interpretation, validation, implementation

Research interests: Predictive biomarkers in lung adenocarcinoma, malignant melanoma, metastatic colorectal cancer, liquid biopsy for solid tumours, profiling in myeloid and lymphoid neoplasms, tumour agnostic testing, standardized variant interpretation

Publications:

  1. Kartolo, A., Feilotter, H., Hopman, W., Fung A., Robinson A. A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors. (2021) Cancer Treatment and Research Communications 27: 100330.doi 10.1016/j.ctarc.2021.100330.
  2. Bebb D, Banerji S, Blais N , Desmeules P , Gill S , Andrea Grin  A, Feilotter H,  Aaron R. Hansen A , Hyrcza M, Krzyzanowska  M, Melosky B , Noujaim J,  Purgina B, Ruether  D, Simmons C , Soulieres D, Torlakovic E  and Tsao M Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults. (2021) Current Oncology 28:523-548.
  3. Fujiyoshi K, Bruford EA, Mroz P, Sims CL, O’Leary TJ, Lo AWI, Chen N, Patel NR, Patel KP, Seliger B, Song M, Monzon FA, Carter AB, Gulley ML, Mockus SM, Phung TL, Feilotter H, Williams HE, Ogino S. Standardizing gene product nomenclature: a call to action. (2021) Proc Natl Acad Sci Sci DOI 10.1073/pnas.2025207118. (Last four authors share senior authorship)
  4. Adler, A., Novelli, V., Ahmad, A., Abiusi, E., Care, M., Nannenberg, E., Feilotter, H., Amenta, S., Mazza, D., Bikker H., Sturm, A., Garcia, J., Ackerman, M., Hershberger, R., Perez, M., Zareba, W., Ware, J., Wilde, A., Gollob, M. An international, multicentred evidence-based reappraisal of genes reported to cause Long QT syndrome. (2020) Circulation 141:418.  (Selected by the Genomic Medicine Working Group of the National Advisory Council for Human Genome Research as one of the top ten papers in 2020 reporting significant advances in genomic medicine (see Manolio et al 2020 AJHG 107_1007)).
  5. Spence, T., Stickle, N., Yu, C., Chow, H., Feilotter, H., Lo, B., McCready, E., Sadikovic, B., Siu, L., Bedard, P., Stockley, T. Inter-laboratory proficiency testing scheme for tumour next-generation sequencing in Ontario: a pilot study. (2019) Currr Oncol 26: 7e17.
  6. Malone, E., Saleh, R., Yu, C., Ahmed, L, Pugh, T., Torchia, J., Bartlett, J., Virtanen, C., Hotte, S., Hilton, J., Welch, S., Robinson, A., McCready, E., Lo, B., Sadikovic, B., Feilotter, H., Hanna, T., Kamel-Reid, S., Stockley, T., Sui, L, Bedard, P. OCTANE (Ontario-wide cancer targeted nucleic acid evaluation): a platform for intraprovincial, national and international clinical data-sharing. (2019) Curr Oncol 26:e618-e623.